Skip to main content

Eloxx Pharmaceuticals, Inc.

ELOX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001035354

No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $40.2M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +22 vs. previous quarter
22
13F valueReported value at the end of Q2 2026
$40.2M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ELOX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ELOX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Eloxx Pharmaceuticals, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 1, 2021 (view filing)Nov 292 daysGeffken Daniel E.INTERIM CFOPPurchase+50.0K$0.72+$36.0KNew position50.0K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Eloxx Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 22 holders
Institutions holding ELOX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Nantahala Capital Management, LLC800,000$11.1M0.34%+800,000New
EcoR1 Capital, LLC400,000$5.55M0.28%+400,000New
Standard Life Aberdeen plc400,000$5.55M0.01%+400,000New
Samsara BioCapital, LLC400,000$5.55M0.46%+400,000New
Siren, L.L.C.400,000$5.55M0.11%+400,000New
Stonepine Capital Management, LLC397,160$5.51M4.20%+397,160New
Vanguard Capital Management LLC78,680$1.09M0.00%+78,680New
Vanguard Fiduciary Trust Co10,602$147.2K0.00%+10,602New
Seven Grand Managers, LLC10,000$138.8K0.01%+10,000New
Morgan Stanley1,544$21.4K0.00%+1,544New